摘要:目的 探究全膝關(guān)節(jié)置換術(shù)(TKA)患者發(fā)生神經(jīng)認(rèn)知功能障礙(PND)的影響因素并構(gòu)建列線圖預(yù)測(cè)模型。方法 收集249例行TKA患者的臨床資料并按照7∶3的比例將患者分為建模隊(duì)列(n=174)和驗(yàn)證隊(duì)列(n=75)。根據(jù)患者是否發(fā)生PND,將建模隊(duì)列分為PND組(n=62)和非PND組(n=112),驗(yàn)證隊(duì)列分為PND組(n=27)和非PND組(n=48)。分析TKA患者發(fā)生PND的影響因素,建立列線圖預(yù)測(cè)模型并進(jìn)行驗(yàn)證。結(jié)果 高衰弱評(píng)分、全身麻醉、單一鎮(zhèn)痛方案、高疼痛視覺(jué)模擬評(píng)分(VAS)是PND的危險(xiǎn)因素,高白蛋白和血紅蛋白水平是PND的保護(hù)因素(均P<0.05)。構(gòu)建列線圖模型,預(yù)測(cè)建模隊(duì)列和驗(yàn)證隊(duì)列發(fā)生PND的曲線下面積(AUC)及其95%CI分別為0.875(0.824~0.925)、0.905(0.835~0.975);校準(zhǔn)曲線分析結(jié)果發(fā)現(xiàn),預(yù)測(cè)患者發(fā)生PND的風(fēng)險(xiǎn)和實(shí)際發(fā)生情況基本吻合,Hosmer-Lemeshow結(jié)果顯示模型擬合較好;臨床決策曲線結(jié)果顯示該模型臨床應(yīng)用價(jià)值較高。結(jié)論 高衰弱評(píng)分、全身麻醉、單一鎮(zhèn)痛方案、高VAS評(píng)分、低白蛋白和低血紅蛋白水平可增加TKA患者發(fā)生PND的風(fēng)險(xiǎn),本研究構(gòu)建的列線圖預(yù)測(cè)模型有助于臨床識(shí)別PND高危人群。
關(guān)鍵詞:關(guān)節(jié)成形術(shù),置換,膝;認(rèn)知功能障礙;Logistic模型;列線圖
中圖分類號(hào):R684 文獻(xiàn)標(biāo)志碼:A DOI:10.11958/20241375
Influencing factors of neurocognitive dysfunction after total knee arthroplasty and the construction of a nomogram model
JIA Fang, LI Ping, LI Jing, YIN Lu
Department of Anesthesiology, Tianjin Hospital, Tianjin 300211, China
Abstract: Objective To explore the influencing factors of neurocognitive dysfunction (PND) in patients with total knee arthroplasty (TKA) and construct a nomogram prediction model. Methods The clinical data of 249 patients with TKA admitted to our hospital from December 2022 to July 2024 were selected. Patients were divided into the modeling queue (n=174) and the verification queue (n=75) according to the ratio of 7∶3. At the same time, according to whether patients developed PND or not, the modeling queue was divided into the PND group (n=62) and the non-PND group (n=112), and the verification queue was divided into the PND group (n=27) and the non-PND group (n=48). The influencing factors of PND in TKA patients were analyzed, and a nomogram prediction model was established to verify. Results High debilitation score, general anesthesia, single analgesic regimen and high VAS score were risk factors of PND, while high albumin and hemoglobin levels were protective factors of PND (P<0.05). The nomogram model was constructed, and the AUC of PND in the modeling queue and the verification queue was 0.875 (95%CI: 0.824-0.925) and 0.905 (95%CI:0.835-0.975) respectively. The results of calibration curve analysis showed that the predicted risk of PND was basically consistent with the actual situation, and the results of Hosmer-Lemeshow showed that the model fit well. The results of clinical decision curve showed that the model had high clinical application value. Conclusion High debilitating score, general anesthesia, single analgesic regimen, high VAS score and low albumin and hemoglobin levels can increase the risk of PND in TKA patients. The nomogram prediction model constructed in this study is helpful for clinical identification of high-risk groups of PND.
Key words: arthroplasty, replacement, knee; cognitive dysfunction; Logistic models; nomograms
有文獻(xiàn)報(bào)道,20歲及以上人群中,每年每10 000人中約有203人新診為膝關(guān)節(jié)骨性關(guān)節(jié)炎疾病[1]。隨著年齡的增長(zhǎng),該病的患病率和發(fā)病率隨之增加,全膝關(guān)節(jié)置換術(shù)(total knee arthroplasty,TKA)是治療終末期膝骨關(guān)節(jié)炎的常見(jiàn)手術(shù)療法[2]。但TKA的大創(chuàng)口、術(shù)后持續(xù)疼痛以及麻醉藥物的使用均與患者術(shù)后神經(jīng)認(rèn)知功能障礙有著密切聯(lián)系[3-4]。麻醉手術(shù)后出現(xiàn)的認(rèn)知功能下降已在2018年被更名為圍手術(shù)期神經(jīng)認(rèn)知障礙(perioperative neurocognitive disorders,PND),PND包括術(shù)前已存在的認(rèn)知障礙、術(shù)后譫妄(postoperative delirium,POD)、術(shù)后神經(jīng)認(rèn)知障礙(neurocognitive disorders,NCD)及術(shù)后延遲神經(jīng)認(rèn)知功能恢復(fù)(delayed recovery of neurocognitive function,DNR),其中接受髖關(guān)節(jié)手術(shù)的患者PND發(fā)生率約為22%[5]。65%以上的老年人群在接受手術(shù)或麻醉后會(huì)發(fā)生PND,可持續(xù)1年甚至更長(zhǎng)[6]。Kitsis等[7]證實(shí),POD是TKA的常見(jiàn)并發(fā)癥,增加了患者其他醫(yī)療并發(fā)癥風(fēng)險(xiǎn)。目前探究TKA患者發(fā)生PND的研究不少,但缺乏一種量化的預(yù)測(cè)工具。本研究通過(guò)構(gòu)建列線圖模型,旨在為臨床預(yù)測(cè)TKA患者術(shù)后并發(fā)PND風(fēng)險(xiǎn)提供更加可靠的評(píng)估工具。
1 對(duì)象與方法
1.1 研究對(duì)象 選擇2022年12月—2024年7月在天津市天津醫(yī)院行TKA的249例患者為研究對(duì)象,其中女167例,男82例。通過(guò)隨機(jī)數(shù)字表法按照7∶3的比例將患者分為建模隊(duì)列(n=174)和驗(yàn)證隊(duì)列(n=75)。納入標(biāo)準(zhǔn):(1)患者經(jīng)保守治療無(wú)效,步行距離<500 m,影像學(xué)及實(shí)驗(yàn)室檢查均具備TKA手術(shù)指征。(2)患者首次行單側(cè)TKA。(3)美國(guó)麻醉醫(yī)師協(xié)會(huì)(American Society of Anesthesiologists,ASA)分級(jí)[8]Ⅰ—Ⅲ級(jí)。(4)入院時(shí)簡(jiǎn)易精神狀態(tài)檢查量表[9](mini-mental state examination,MMSE)評(píng)分>26分,日常生活活動(dòng)能力量表[10](activities of daily living scale,ADLs)評(píng)分>60分,畫(huà)鐘表試驗(yàn)為陰性。(5)年齡50~80歲。(6)臨床資料完整。排除標(biāo)準(zhǔn):(1)合并免疫系統(tǒng)疾病或凝血功能障礙。(2)合并嚴(yán)重感染性疾病。(3)合并心、肝、腎等重要臟器疾病。(4)術(shù)前合并阿爾茨海默病、帕金森綜合征、腦卒中等神經(jīng)或精神疾病。(5)不適用于手術(shù)治療,對(duì)術(shù)中使用藥物過(guò)敏或存在禁忌證。(6)既往有癡呆、POD病史或其他神經(jīng)系統(tǒng)疾病。本研究經(jīng)醫(yī)院倫理委員會(huì)批準(zhǔn)(倫理批件號(hào):TY2022J117)。
1.2 研究方法
1.2.1 PND判定方法 由臨床經(jīng)驗(yàn)≥5年且經(jīng)過(guò)培訓(xùn)的臨床醫(yī)師在患者入院時(shí)、術(shù)后3 d、術(shù)后7 d評(píng)估MMSE得分情況,若患者術(shù)后MMSE評(píng)分相較于術(shù)前評(píng)分下降≥2分,則表示出現(xiàn)神經(jīng)認(rèn)知功能障礙,判定為發(fā)生PND。PND總發(fā)生率為35.74%(89/249),建模隊(duì)列62例,驗(yàn)證隊(duì)列27例。根據(jù)患者是否發(fā)生PND,將建模隊(duì)列分為PND組(n=62)和非PND組(n=112),驗(yàn)證隊(duì)列分為PND組(n=27)和非PND組(n=48)。
1.2.2 一般資料收集 從醫(yī)院病歷系統(tǒng)中調(diào)取患者的一般資料,包括性別、年齡、身體質(zhì)量指數(shù)(body mass index,BMI)、是否合并呼吸系統(tǒng)疾?。ㄉ虾粑栏腥尽⒅夤苎?、肺炎等)、是否合并基礎(chǔ)疾?。ü谛牟 ⒏哐獕骸⒏咧Y、糖尿病、既往腦梗死病史、抑郁史等)、術(shù)前衰弱評(píng)分[11]、術(shù)側(cè)、手術(shù)時(shí)間、麻醉時(shí)間、術(shù)中出血量、麻醉方式(全身麻醉、全身麻醉復(fù)合硬膜外麻醉)、術(shù)后鎮(zhèn)痛方案(單一鎮(zhèn)痛方案、多模式鎮(zhèn)痛)、術(shù)后疼痛視覺(jué)模擬評(píng)分(visual analog scale,VAS)[12]等。
1.2.3 實(shí)驗(yàn)室檢查 術(shù)前抽取患者空腹靜脈血5 mL,以" " " 3 000 r/min離心5 min,使用上海雅培C16000全自動(dòng)生化分析儀檢測(cè)白蛋白(ALB);使用深圳邁瑞B(yǎng)C-5380型號(hào)的血細(xì)胞分析儀檢測(cè)紅細(xì)胞計(jì)數(shù)(RBC)、血紅蛋白(HB)、白細(xì)胞計(jì)數(shù)(WBC)、中性粒細(xì)胞計(jì)數(shù)(NEU)、淋巴細(xì)胞計(jì)數(shù)(LYM)等。
1.3 統(tǒng)計(jì)學(xué)方法 采用SPSS 26.0和R-studio 4.2.1軟件分析數(shù)據(jù),符合正態(tài)分布的計(jì)量資料以[[x] ±s
]表示,組間比較使用獨(dú)立樣本t檢驗(yàn),計(jì)數(shù)資料以例表示,組間比較使用χ2檢驗(yàn)。多因素Logistic回歸分析TKA患者發(fā)生PND的影響因素,基于多因素回歸分析結(jié)果建立列線圖預(yù)測(cè)模型,繪制校準(zhǔn)曲線評(píng)估列線圖的預(yù)測(cè)效能,繪制受試者工作特征(ROC)曲線,以曲線下面積(AUC)評(píng)價(jià)列線圖模型區(qū)分度,繪制校準(zhǔn)曲線驗(yàn)證模型校準(zhǔn)度并進(jìn)行Hosmer-Lemeshow檢驗(yàn),繪制臨床決策曲線(DCA)評(píng)價(jià)模型的臨床獲益度。P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 建模隊(duì)列與驗(yàn)證隊(duì)列基線資料對(duì)比 建模隊(duì)列與驗(yàn)證隊(duì)列基線資料比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(均P>0.05),見(jiàn)表1。
2.2 建模隊(duì)列PND組與非PND組基線資料對(duì)" " "比 與非PND組相比,PND組衰弱評(píng)分更高,全身麻醉和單一鎮(zhèn)痛方案比例更高,VAS評(píng)分更高,ALB和HB水平更低(均P<0.05),其余資料差異無(wú)統(tǒng)計(jì)學(xué)意義,見(jiàn)表2。
2.3 TKA患者發(fā)生PND的影響因素分析 以是否發(fā)生PND為因變量(否=0,是=1),以衰弱評(píng)分、麻醉方式(全身麻醉=1,全身麻醉復(fù)合硬膜外麻醉=0)、鎮(zhèn)痛方案(單一鎮(zhèn)痛方案=1,多模式鎮(zhèn)痛=0)、VAS評(píng)分、ALB、HB為自變量,納入多因素Logistic分析。結(jié)果顯示,高衰弱評(píng)分、全身麻醉、單一鎮(zhèn)痛方案、高VAS評(píng)分是PND的危險(xiǎn)因素,高ALB和HB水平是PND的保護(hù)因素(均P<0.05),見(jiàn)表3。
2.4 TKA患者發(fā)生PND的列線圖預(yù)測(cè)模型 根據(jù)多因素分析結(jié)果構(gòu)建Nomogram預(yù)測(cè)模型,各預(yù)測(cè)因子評(píng)分相加為模型總分,根據(jù)總分對(duì)應(yīng)TKA患者發(fā)生PND的風(fēng)險(xiǎn),見(jiàn)圖1。
2.5 列線圖模型區(qū)分度 繪制列線圖模型在建模隊(duì)列和驗(yàn)證隊(duì)列中的ROC曲線,建模隊(duì)列AUC(95% CI)為0.875(0.824~0.925),驗(yàn)證隊(duì)列為0.905(0.835~0.975),模型區(qū)分能力良好,見(jiàn)圖2、3。
2.6 列線圖模型校準(zhǔn)度 繪制列線圖模型在建模隊(duì)列和驗(yàn)證隊(duì)列中的校準(zhǔn)曲線,Hosmer-Lemeshow檢驗(yàn)結(jié)果顯示,預(yù)測(cè)結(jié)果與實(shí)際結(jié)果一致性較好(χ2分別為9.022、9.244,均P>0.05),模型校準(zhǔn)能力良好,見(jiàn)圖4、5。
2.7 決策分析曲線 繪制列線圖模型在建模隊(duì)列和驗(yàn)證隊(duì)列中的決策分析曲線,結(jié)果顯示,列線圖模型曲線在>0.1的閾值概率區(qū)間均高于其他2條極端線條,說(shuō)明閾值概率>10%時(shí)使用該列線圖模型干預(yù)可使患者在臨床中獲益,見(jiàn)圖6、7。
3 討論
在外科手術(shù)患者中,PND的發(fā)生不在少數(shù),但臨床尚無(wú)關(guān)于PND適應(yīng)證的特效治療藥物,這使得臨床研究重點(diǎn)不得不轉(zhuǎn)向?yàn)轭A(yù)防策略的探索[13]。如何在早期對(duì)TKA患者采取預(yù)防措施,從而避免或減少術(shù)后PND的發(fā)生,已成為麻醉科、精神科及外科醫(yī)生共同關(guān)注的熱點(diǎn)。本研究通過(guò)探究TKA患者發(fā)生PND的影響因素并構(gòu)建列線圖預(yù)測(cè)模型,有利于臨床制定防治策略,進(jìn)一步開(kāi)發(fā)針對(duì)性治療手段。
本研究分析發(fā)現(xiàn),高衰弱評(píng)分、術(shù)中全身麻醉、術(shù)后單一鎮(zhèn)痛、術(shù)后高VAS評(píng)分、術(shù)前ALB和HB水平降低均增加了PND發(fā)生的風(fēng)險(xiǎn)。高衰弱評(píng)分意味著患者健康狀況較差,生理儲(chǔ)備能力下降,手術(shù)危險(xiǎn)性更高,患者會(huì)對(duì)手術(shù)和麻醉產(chǎn)生更強(qiáng)的應(yīng)激反應(yīng),導(dǎo)致炎癥反應(yīng)更劇烈并影響血腦屏障的完整性,進(jìn)而影響神經(jīng)細(xì)胞膜穩(wěn)定,患者更易出現(xiàn)中樞神經(jīng)系統(tǒng)損傷。此外,術(shù)前生理功能衰弱的患者術(shù)后恢復(fù)時(shí)間更長(zhǎng),體內(nèi)正常的能量供應(yīng)和細(xì)胞功能受到影響,增加了PND的發(fā)生風(fēng)險(xiǎn)[14]。Gracie等[15-16]研究同樣指出術(shù)前衰弱增加了POD的發(fā)生風(fēng)險(xiǎn)。術(shù)中行全身麻醉的患者發(fā)生PND的風(fēng)險(xiǎn)高于全身麻醉復(fù)合硬膜外麻醉的患者,可能是因?yàn)閱我蝗砺樽頃?huì)導(dǎo)致患者交感神經(jīng)系統(tǒng)過(guò)度激活,而聯(lián)合硬膜外麻醉能夠阻斷脊神經(jīng)傳導(dǎo),減少兒茶酚胺等血管收縮物質(zhì)的釋放,并通過(guò)擴(kuò)張阻滯平面以下血管增加下肢血流量,降低因缺血導(dǎo)致的神經(jīng)損傷[17];另一方面,也可能與全身麻醉復(fù)合硬膜外麻醉能夠有效緩解患者術(shù)后疼痛并抑制炎癥因子釋放,調(diào)節(jié)術(shù)后免疫和代謝功能有關(guān)[18]。手術(shù)損傷及術(shù)后炎癥反應(yīng)均可使患者脊髓和大腦痛覺(jué)感受器敏感度增加,術(shù)后多模式鎮(zhèn)痛方案能夠結(jié)合多種藥物和方法通過(guò)多種機(jī)制共同控制患者術(shù)后疼痛反應(yīng),降低中樞神經(jīng)系統(tǒng)應(yīng)激和炎癥反應(yīng),減少大腦損傷。而單一鎮(zhèn)痛方案不足以全面緩解疼痛,無(wú)法有效抑制術(shù)后脊髓和大腦痛覺(jué)感受器的敏感化,可能加劇機(jī)體炎癥反應(yīng)并導(dǎo)致神經(jīng)遞質(zhì)失衡,增加PND的發(fā)生風(fēng)險(xiǎn)。此外,TKA術(shù)后嚴(yán)重的疼痛反應(yīng)會(huì)激活患者大腦炎癥通路,釋放細(xì)胞因子和趨化因子,同時(shí)激活下丘腦-垂體-腎上腺軸,損害神經(jīng)元與突觸,導(dǎo)致大腦神經(jīng)系統(tǒng)失衡,因此術(shù)后VAS評(píng)分較高的患者更易發(fā)生PND。術(shù)后炎癥反應(yīng)可導(dǎo)致患者中樞神經(jīng)系統(tǒng)中的Aβ淀粉樣蛋白高表達(dá)及tau蛋白的高度磷酸化,使得神經(jīng)毒性物質(zhì)Aβ淀粉樣蛋白進(jìn)一步誘導(dǎo)神經(jīng)元凋亡,而ALB則能夠與Aβ淀粉樣蛋白相結(jié)合并抑制其聚集與纖維化,降低Aβ神經(jīng)毒性,因此術(shù)前較低的ALB水平可能損傷患者腦神經(jīng),并與術(shù)后PND的發(fā)生有關(guān)[19]。而術(shù)前HB降低可導(dǎo)致機(jī)體攜氧能力降低,腦細(xì)胞缺氧,直接影響腦細(xì)胞正常結(jié)構(gòu)和功能,導(dǎo)致神經(jīng)遞質(zhì)失衡而誘發(fā)腦水腫,最終導(dǎo)致腦細(xì)胞喪失正?;顒?dòng)能力和神經(jīng)系統(tǒng)紊亂,從而增加術(shù)后PND發(fā)生風(fēng)險(xiǎn)[20]。Wang等[21]研究顯示,貧血與癡呆風(fēng)險(xiǎn)的增加有關(guān)。Sun等[22]研究發(fā)現(xiàn),血清ALB水平與認(rèn)知功能顯著相關(guān),其水平升高有助于降低帕金森疾病患者的死亡風(fēng)險(xiǎn),與本研究結(jié)果相符。但本研究中,年齡和BMI未入選PND發(fā)生的影響因素,與Rong等[23]研究結(jié)果不同,可能與納入人群不同有關(guān)。相較于以往研究,本研究將麻醉方式、術(shù)后鎮(zhèn)痛方案、術(shù)前ALB及HB水平納入因素分析中,為臨床管理和預(yù)防PND提供了新視角。
本研究構(gòu)建了列線圖預(yù)測(cè)模型并進(jìn)行驗(yàn)證,結(jié)果顯示列線圖模型預(yù)測(cè)建模組和驗(yàn)證組發(fā)生PND的AUC分別為0.875(95%CI:0.824~0.925)和0.905(95%CI:0.835~0.975),校準(zhǔn)曲線顯示,列線圖預(yù)測(cè)建模組和驗(yàn)證組患者發(fā)生PND的概率與實(shí)際發(fā)生率一致性較好,同時(shí)具有較高的臨床獲益度。本次構(gòu)建的列線圖模型有助于醫(yī)護(hù)人員通過(guò)數(shù)字化模型及早識(shí)別TKA患者發(fā)生PND的危險(xiǎn)因素,可在以后的臨床工作中通過(guò)術(shù)前加強(qiáng)營(yíng)養(yǎng)支持、實(shí)施個(gè)體化麻醉和鎮(zhèn)痛方案、采取更有效的術(shù)后疼痛管理方案、密切監(jiān)測(cè)并糾正患者術(shù)前ALB及HB水平等措施積極糾正PND發(fā)生的潛在危險(xiǎn)因素。但本研究為回顧性分析,受試者臨床資料有限,數(shù)據(jù)來(lái)自單中心,指標(biāo)和樣本選擇可能存在一定偏倚,今后可通過(guò)多中心、大樣本、前瞻性研究進(jìn)一步探討。
參考文獻(xiàn)
[1] CUI A,LI H,WANG D,et al. Global,regional prevalence,incidence and risk factors of knee osteoarthritis in population-based studies[J]. EClinicalMedicine,2020,29-30:100587. doi:10.1016/j.eclinm.2020.100587.
[2] SAFFARINI M,HIRSCHMANN M T,BONNIN M. Personalisation and customisation in total knee arthroplasty:the paradox of custom knee implants[J]. Knee Surg Sports Traumatol Arthrosc,2023,31(4):1193-1195. doi:10.1007/s00167-023-07385-0.
[3] LIU S,XV L,WU X,et al. Potential value of preoperative fasting blood glucose levels in the identification of postoperative delirium in non-diabetic older patients undergoing total hip replacement:the perioperative neurocognitive disorder and biomarker lifestyle study[J]. Front Psychiatry,2022,13:941048. doi:10.3389/fpsyt.2022.941048.
[4] 申遠(yuǎn). 麻醉與圍手術(shù)期神經(jīng)認(rèn)知功能障礙[J]. 老年醫(yī)學(xué)與保健,2023,29(4):669-673. SHEN Y. Neurocognitive dysfunction during anesthesia and perioperative period[J]. Geriatrics and Health Care,2023,29(4):669-673. doi:10.3969/j.issn.1008-8296.2023.04.003.
[5] 劉健慧,胡佳勇,杜雪. 圍手術(shù)期神經(jīng)認(rèn)知功能障礙的現(xiàn)狀與未來(lái)[J]. 同濟(jì)大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2020,41(1):9-18. LIU J H,HU J Y,DU X. Current situation and future of neurocognitive dysfunction in perioperative period[J]. Journal of Tongji University(Medical Edition),2020,41(1):9-18. doi:10.16118/j.1008-0392.2020.01.003.
[6] EVERED L,ATKINS K,SILBERT B,et al. Acute peri-operative neurocognitive disorders:a narrative review[J]. Anaesthesia,2022,77 Suppl 1:34-42. doi:10.1111/anae.15613.
[7] KITSIS P,ZISIMOU T,GKIATAS I,et al. Postoperative delirium and postoperative cognitive dysfunction in patients with elective hip or knee arthroplasty:a narrative review of the literature[J]. Life(Basel),2022,12(2):314. doi:10.3390/life12020314.
[8] HORVATH B,KLOESEL B,TODD M M,et al. The evolution,current value,and future of the American Society of Anesthesiologists Physical Status Classification System[J]. Anesthesiology,2021,135(5):904-919. doi: 10.1097/ALN.0000000000003947.
[9] JIA X,WANG Z,HUANG F,et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population:a cross-sectional study[J]. BMC Psychiatry,2021,21(1):485. doi:10.1186/s12888-021-03495-6.
[10] DEVI J. The scales of functional assessment of Activities of Daily Living in geriatrics[J]. Age Ageing,2018,47(4):500-502. doi:10.1093/ageing/afy050.
[11] 景冬梅,沈沖,莫永珍,等. 中文版衰弱量表在老年衰弱評(píng)價(jià)中的信效度研究[J]. 護(hù)士進(jìn)修雜志,2021,36(9):784-788. JING D M,SHEN C,MO Y Z,et al. Study on the reliability and validity of Chinese version of asthenia scale in the evaluation of senile asthenia [J]. Journal of Nurse Training,2021,36(9):784-788. doi:10.16821/j.cnki.hsjx.2021.09.004.
[12] 孫兵,車曉明.視覺(jué)模擬評(píng)分法(VAS)[J]. 中華神經(jīng)外科雜志,2012,28(6):645. SUN B,CHE X M. Visual analogue scale(VAS)[J]. Chinese Journal of Neurosurgery,2012,28(6):645.
[13] QEVA E,SOLLAZZO C,BILOTTA F. Insulin signaling in the central nervous system,a possible pathophysiological mechanism of anesthesia-induced delayed neurocognitive recovery/postoperative neurocognitive disorder:a narrative review[J]. Expert Rev Neurother,2022,22(10):839-847. doi:10.1080/14737175.2022.2144234.
[14] YUAN Y,PENG C,BURR J A,et al. Frailty,cognitive impairment,and depressive symptoms in Chinese older adults:an eight-year multi-trajectory analysis[J]. BMC Geriatr,2023,23(1):843. doi:10.1186/s12877-023-04554-1.
[15] GRACIE T J,CAUFIELD-NOLL C,WANG N Y,et al. The association of preoperative frailty and postoperative delirium:a meta-analysis[J]. Anesth Analg,2021,133(2):314-323. doi:10.1213/ANE.0000000000005609.
[16] WARD D D,RANSON J M,WALLACE L,et al. Frailty,lifestyle,genetics and dementia risk[J]. J Neurol Neurosurg Psychiatry,2022,93(4):343-350. doi:10.1136/jnnp-2021-327396.
[17] GRICOURT Y,CUVILLON P. Epidural analgesia combined with general anaesthesia to prevent cognitive dysfunction:more than a single strategy?[J]. Anaesth Crit Care Pain Med,2022,41(5):101136. doi:10.1016/j.accpm.2022.101136.
[18] 靳洪震,王巖,柏豪豪,等. 全膝關(guān)節(jié)置換術(shù)治療膝骨關(guān)節(jié)炎圍手術(shù)期研究進(jìn)展[J]. 中國(guó)中西醫(yī)結(jié)合外科雜志,2024,30(1):144-149. JIN H Z,WANG Y,BO H H,et al. Research progress of total knee arthroplasty for knee osteoarthritis in perioperative period[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine,2024,30(1):144-149. doi:10.3969/j.issn.1007-6948.2024.01.029
[19] KIM J W,BYUN M S,LEE J H,et al. Serum albumin and beta-amyloid deposition in the human brain[J]. Neurology,2020,95(7):e815-e826. doi:10.1212/WNL.0000000000010005.
[20] KOMURCU O,DOST B,OZDEMIR E,et al. Red blood cell transfusion and hemoglobin level on neurological outcome in the first 24 hours of traumatic brain injury[J]. Am J Emerg Med,2022,59:74-78. doi:10.1016/j.ajem.2022.06.058.
[21] WANG J,WANG C,LI X,et al. Association of anemia with cognitive function and dementia among older adults:the role of inflammation[J]. J Alzheimers Dis,2023,96(1):125-134. doi:10.3233/JAD-230483.
[22] SUN S,WEN Y,LI Y. Serum albumin,cognitive function,motor impairment,and survival prognosis in Parkinson disease[J]. Medicine (Baltimore),2022,101(37):e30324. doi:10.1097/MD.0000000000030324.
[23] RONG X,DING Z C,YU H D,et al. Risk factors of postoperative delirium in the knee and hip replacement patients:a systematic review and meta-analysis[J]. J Orthop Surg Res,2021,16(1):76. doi:10.1186/s13018-020-02127-1.
(2024-09-18收稿 2024-11-27修回)
(本文編輯 李國(guó)琪)
作者單位:天津市天津醫(yī)院麻醉科(郵編300211)
作者簡(jiǎn)介:賈方(1977),女,副主任醫(yī)師,主要從事麻醉學(xué)的基礎(chǔ)與臨床方面研究。E-mail:jiafangjia77@163.com
引用本文:賈方,李平,李靜,等. 全膝關(guān)節(jié)置換術(shù)后神經(jīng)認(rèn)知功能障礙的影響因素及列線圖模型的構(gòu)建[J]. 天津醫(yī)藥,2025,53(3):287-292. JIA F,LI P,LI J,et al. Influencing factors of neurocognitive dysfunction after total knee arthroplasty and the construction of a nomogram model[J]. Tianjin Med J,2025,53(3):287-292. doi:10.11958/20241375.